Comparative Effectiveness of Immunotherapies for Untreated Advanced Non-Small Cell Lung Cancer in Real-World Clinical Practice: a Japanese Cancer Registry Cohort Study DOI Creative Commons
Akito Miyazaki,

Kei Kunimasa,

Toshitaka Morishima

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 11, 2024

Abstract Objectives No direct comparative study has evaluated first-line immunomonotherapy and immunochemotherapy regimens for advanced non–small cell lung cancer (NSCLC). To compare the effectiveness of them, focusing on time to treatment failure (TTF) overall survival (OS). Materials Methods This retrospective, multicenter cohort at 68 hospitals in Osaka Prefecture, Japan, included patients with NSCLC who received or as initial between January 2019 December 2021. Data were collected from registry administrative databases. The median follow-up was 267 days (IQR, 143–247 days). endpoints OS TTF comparisons among regimens, further comparing atezolizumab-chemotherapy (ATZ-chemo), pembrolizumab-chemotherapy (Pembro-chemo), nivolumab–ipilimumab-chemotherapy (NIV + IPI-chemo) regimens. Baseline characteristics obtained, propensity score-matched analyses performed. Results We identified 2,101 Stage IV treated ATZ, Pembro, NIV IPI. After score matching, showed no significant difference (median: 247 vs. 233 days; P = 0.74), but significantly improved 653 492 < 0.05). Among chemotherapy combinations, Pembro-chemo group had longer (287 211 0.05) (not reached 609 0.03) compared ATZ-chemo group. Comparing IPI-chemo (239 217 0.53) (814 not reached; 0.26). Conclusions suggests that pembrolizumab-containing may contribute more prolonged survival.

Language: Английский

Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions DOI
Yibei Wang, Mohammed Safi, Fred R. Hirsch

et al.

Nature Reviews Clinical Oncology, Journal Year: 2025, Volume and Issue: 22(3), P. 200 - 214

Published: Jan. 6, 2025

Language: Английский

Citations

1
Traditional Chinese medicine in lung cancer treatment DOI Creative Commons
Zhichao Xi,

Rongchen Dai,

Yufei Ze

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: Feb. 26, 2025

Lung cancer remains a major global health challenge and one of the leading causes cancer-related deaths worldwide. Despite significant advancements in treatment, challenges such as drug resistance, side effects, metastasis recurrence continue to impact patient outcomes quality life. In response, there is growing interest complementary integrative approaches care. Traditional Chinese medicine (TCM), with its long history, abundant clinical experience, holistic perspective individualized approach, has garnered increasing attention for role lung prevention management. This review provides comprehensive overview advances TCM covering theoretical foundation, treatment principles, experiences evidence supporting efficacy. We also provide systematic summary preclinical mechanisms, through which impacts cancer, including induction cell death, reversal inhibition modulation immune responses. Additionally, future prospects are discussed, offering insights into expanded application integration modern address this challenging disease.

Language: Английский

Citations

1
Regimen Selection for Chemoimmunotherapy in Non-Squamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multi-Center Retrospective Cohort Study DOI
Tae Hata, Tadaaki Yamada, Yasuhiro Gotô

et al.

Clinical Lung Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
High Antigenicity for Treg Cells Confers Resistance to PD‐1 Blockade Therapy via High PD‐1 Expression in Treg Cells DOI Creative Commons
Hisae Matsuura, Takamasa Ishino,

Toshifumi Ninomiya

et al.

Cancer Science, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

ABSTRACT Regulatory T (T reg ) cells have an immunosuppressive function, and programmed death‐1 (PD‐1)‐expressing reportedly induce resistance to PD‐1 blockade therapies through their reactivation. However, the effects of antigenicity on expression in therapy remain unclear. Here, we show that gain high antigen with antigenicity. Additionally, tumors for were resistant vivo due + ‐cell infiltration. Because such cytotoxic lymphocyte (CTLA)‐4 expression, could be overcome by combination anti‐CTLA‐4 monoclonal antibody (mAb). Patients who responded anti‐PD‐1 mAbs sequentially after primary monotherapy showed cell We propose confers via cells, which can mAb.

Language: Английский

Citations

0
Cruciferae-based oral selenium delivery system reprograms antitumor response and enhances the anti-tumor potency of natural killer cells DOI

Shuoshan Li,

Guizhen Li, Kexin Guo

et al.

Nano Today, Journal Year: 2025, Volume and Issue: 62, P. 102713 - 102713

Published: March 17, 2025

Language: Английский

Citations

0
PD-L1/PD-1 checkpoint pathway regulates astrocyte morphogenesis and myelination during brain development DOI
Yanyan Wang, Mengtian Zhang, Tianyu Zhang

et al.

Molecular Psychiatry, Journal Year: 2025, Volume and Issue: unknown

Published: March 31, 2025

Language: Английский

Citations

0
Comparative effectiveness of immunotherapeutic regimens for untreated advanced non-small-cell lung cancer in real-world clinical practice: a Japanese cancer registry cohort study DOI
Akito Miyazaki, Kei Kunimasa, Toshitaka Morishima

et al.

ESMO Real World Data and Digital Oncology, Journal Year: 2025, Volume and Issue: 8, P. 100137 - 100137

Published: April 14, 2025

Language: Английский

Citations

0
Efficacy and safety of immune checkpoint inhibitors for brain metastases of non-small cell lung cancer: a systematic review and network meta-analysis DOI Creative Commons
Bin Liu, Jie Chen, Mingqi Luo

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: April 16, 2025

Previous studies have demonstrated that immune checkpoint inhibitors (ICIs) significantly improve prognosis in lung cancer patients with brain metastases (BMs). This systematic review and network meta-analysis aims to evaluate the efficacy safety of 10 ICIs recommended by 2024 Chinese Society Clinical Oncology guidelines for treating non-small cell (NSCLC) without driver genes, focusing on NSCLC presenting BMs. A comprehensive literature search PubMed, Embase, Cochrane Library was conducted through June identify eligible controlled trials head-to-head randomized investigating Pairwise meta-analyses were performed using hazard ratios (HRs) relative risks (RRs) 95% confidence intervals (CIs). Treatment ranked hierarchically surface under cumulative ranking curve (SUCRA). Sixteen from 11 studies, encompassing 1,274 BMs, included. The improved overall survival (OS: HR, 0.66; CI, 0.52-0.85; P = 0.001) progression-free (PFS: 0.67; 0.54-0.84; < 0.001). SUCRA identified pembrolizumab as most effective agent OS improvement (SUCRA 71%), while camrelizumab showed superior PFS benefits 92%). associated increased objective response rates (RR: 1.52; 1.13-2.06; 0.006), but elevated immune-mediated adverse events 2.50; 1.46-4.30; grade 3-5 infusion reaction 6.39; 1.53-26.69; 0.011). demonstrate compared chemotherapy emerging optimal choices improvement, respectively. However, vigilant monitoring reactions remains critical clinical practice.

Language: Английский

Citations

0
Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens DOI Creative Commons
Mayu Sugai,

Yoshiaki Amino,

Seitaro Fujishima

et al.

Lung Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 108555 - 108555

Published: April 1, 2025

Language: Английский

Citations

0
Comparative Effectiveness of Immunotherapies for Untreated Advanced Non-Small Cell Lung Cancer in Real-World Clinical Practice: a Japanese Cancer Registry Cohort Study DOI Creative Commons
Akito Miyazaki,

Kei Kunimasa,

Toshitaka Morishima

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 11, 2024

Abstract Objectives No direct comparative study has evaluated first-line immunomonotherapy and immunochemotherapy regimens for advanced non–small cell lung cancer (NSCLC). To compare the effectiveness of them, focusing on time to treatment failure (TTF) overall survival (OS). Materials Methods This retrospective, multicenter cohort at 68 hospitals in Osaka Prefecture, Japan, included patients with NSCLC who received or as initial between January 2019 December 2021. Data were collected from registry administrative databases. The median follow-up was 267 days (IQR, 143–247 days). endpoints OS TTF comparisons among regimens, further comparing atezolizumab-chemotherapy (ATZ-chemo), pembrolizumab-chemotherapy (Pembro-chemo), nivolumab–ipilimumab-chemotherapy (NIV + IPI-chemo) regimens. Baseline characteristics obtained, propensity score-matched analyses performed. Results We identified 2,101 Stage IV treated ATZ, Pembro, NIV IPI. After score matching, showed no significant difference (median: 247 vs. 233 days; P = 0.74), but significantly improved 653 492 < 0.05). Among chemotherapy combinations, Pembro-chemo group had longer (287 211 0.05) (not reached 609 0.03) compared ATZ-chemo group. Comparing IPI-chemo (239 217 0.53) (814 not reached; 0.26). Conclusions suggests that pembrolizumab-containing may contribute more prolonged survival.

Language: Английский

Citations

0